Cargando…
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response
Early in the COVID-19 pandemic, data suggested that males had a higher risk of developing severe disease and that androgen deprivation therapy might be associated with protection. Combined with the fact that TMPRSS2 (transmembrane serine protease 2), a host entry factor for the SARS-CoV-2 virus, was...
Autores principales: | Qiao, Yuanyuan, Wotring, Jesse W., Zheng, Yang, Zhang, Charles J., Zhang, Yuping, Jiang, Xia, Pretto, Carla D., Eyunni, Sanjana, Parolia, Abhijit, He, Tongchen, Cheng, Caleb, Cao, Xuhong, Wang, Rui, Su, Fengyun, Ellison, Stephanie J., Wang, Yini, Qin, Jun, Yan, Honghua, Zhou, Qianxiang, Ma, Liandong, Sexton, Jonathan Z., Chinnaiyan, Arul M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372636/ https://www.ncbi.nlm.nih.gov/pubmed/37459541 http://dx.doi.org/10.1073/pnas.2221809120 |
Ejemplares similares
-
Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2
por: Qiao, Yuanyuan, et al.
Publicado: (2021) -
Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection
por: Qiao, Yuanyuan, et al.
Publicado: (2023) -
Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer
por: Parolia, Abhijit, et al.
Publicado: (2019) -
Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis
por: Gu, Yue, et al.
Publicado: (2021) -
Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature
por: Yang, Da‐Wei, et al.
Publicado: (2023)